Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...
CONCORD, Mass., May 29, 2024--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that ...
BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative ...
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET Arbutus will hold a conference call at 8:00 am ET on Monday, June 27, 2022, to ...
CAMBRIDGE, Mass., April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract ...
SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) ...
CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its ...
Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting CAMBRIDGE, Mass., Mar 31, 2008 -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback